An in silico evaluation of treatment regimens for recurrent Clostridium difficile infection.

about

An in silico evaluation of treatment regimens for recurrent Clostridium difficile infection.

Item

http://www.wikidata.org/entity/Q40085926

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

An in silico evaluation of tre ...... ostridium difficile infection.

@en

type

Item

label

An in silico evaluation of tre ...... ostridium difficile infection.

@en

prefLabel

An in silico evaluation of tre ...... ostridium difficile infection.

@en

P1476

An in silico evaluation of tre ...... lostridium difficile infection

@en

P2093

Alexander H Rickard

http://www.w3.org/2001/XMLSchema#string

Anurag N Malani

http://www.w3.org/2001/XMLSchema#string

Betsy Foxman

http://www.w3.org/2001/XMLSchema#string

Min Zhang

http://www.w3.org/2001/XMLSchema#string

Natalia Blanco

http://www.w3.org/2001/XMLSchema#string

Seth Walk

http://www.w3.org/2001/XMLSchema#string

P2860

OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection

Clostridium difficile spore biology: sporulation, germination, and spore structural proteins

Clostridium difficile infection: new developments in epidemiology and pathogenesis

A system model of oral glucose absorption: validation on gold standard data.

The relationship between phenotype, ribotype, and clinical disease in human Clostridium difficile isolates.

Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection.

Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.

Reconsidering the sporulation characteristics of hypervirulent Clostridium difficile BI/NAP1/027.

Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).

Fidaxomicin versus vancomycin for Clostridium difficile infection.

P304

e0182815

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0182815

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Marisa C Eisenberg

P577

2017-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28800598

http://www.w3.org/2001/XMLSchema#string

P921

Clostridium difficile

P932

5553947

http://www.w3.org/2001/XMLSchema#string